Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ovarian Cancer Screening & Extended Mortality Rates

Gynecol Oncol; ePub 2016 Sep 9; Pinsky, et al

Screening with CA-125 and transvaginal ultrasound (TVU) did not reduce ovarian cancer mortality after 15 years median follow-up, according to a recent study. Participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were randomized from 1993 to 2001 at 10 US centers to an intervention arm (n=39,105) or usual care arm (n=39,111). Intervention arm women were screened for ovarian cancer with annual TVU (4 years) and CA-125 (6 years), with a fixed cutoff at 35 U/mL for CA-125. Median follow-up was 14.7 years in each arm and maximum follow-up 19.2 years. Researchers found:

• There were 187 (intervention) and 176 (usual care) deaths from ovarian cancer (RR, 1.06).

• Risk ratios were similar for study years 0 to 7(RR, 1.06) and 14+ (RR, 1.09).

• All-cause mortality has a risk ratio of 1.01.

• Ovarian cancer specific survival was not significantly different across trial arms.

Citation:

Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. [Published online ahead of print September 9, 2016]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.08.334.